Results 31 to 40 of about 1,279,543 (154)

Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics

Acta Pharmaceutica Sinica B, 2022
Diabetes mellitus is a major health problem with increasing prevalence at a global level. The discovery of insulin in the early 1900s represented a major breakthrough in diabetes management, with further milestones being subsequently achieved with the ...
Carlos Bendicho-Lavilla, Iria Seoane-Viaño, Francisco J. Otero-Espinar, Asteria Luzardo-Álvarez   +3 more
doaj   +1 more source

Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016Plain-language summary

Kidney Medicine, 2021
Background: Information regarding the use of glucose-lowering medications in patients with chronic kidney disease (CKD) is limited. Study Design: Retrospective cohort study.
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, Wendy L. St. Peter   +3 more
doaj   +1 more source

Functional study of amylin and regulation of amylin receptor

, 2010
Amylin, a 37 amino acid peptide secreted from pancreatic beta cells upon stimulation by meal/glucose, belongs to the family of the calcitonin or calcitonin gene-related peptide (CGRP) and shares up to 50% homology with CGRP, which is a well-documented ...
Huang, Xiaofang
core   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Characterization of the 5-HT(7) receptor as a new therapeutic target for the treatment of pain [PDF]

, 2012
[eng] The work showed in this Thesis has been part of the “5-HT7 and neuropathic pain” project in the pharmaceutical company Esteve. Thus, the aim of this Thesis was in line with the goal of the 5-HT7 project at Esteve, focused on drug discovery of 5-HT7
Brenchat Barberà, Àlex
core   +6 more sources

Protecting CEACAM1 Expression Prevents Diet‐Induced Metabolic Dysfunction and Hepatic Fibrosis in Male Mice

Obesity, EarlyView.
ABSTRACT Objective High‐fat diet represses Ceacam1 transcription via a PPARα‐mediated mechanism to cause insulin resistance before inflammation develops. The current study investigated whether mutating PPRE‐RXRα in Ceacam1 promoter prevents diet‐induced metabolic abnormalities and hepatic fibrosis in male C57BL6/J mice.
Raziyeh Abdolahipour, Saja S. Khuder, William M. Philbrick, Agnes O. Portuphy, Getachew D. Belew, Hatem G. Fallouh, Harrison T. Muturi, Boyeon Kim, Jason K. Kim, Sonia M. Najjar   +9 more
wiley   +1 more source

Guanosine nucleotides regulate B2 kinin receptor affinity of agonists but not of antagonists: Discussion of a model proposing receptor precoupling to G protein [PDF]

, 2000
The effect of nucleotides on binding of the B2 kinin (BK) receptor agonist {[}H-3]BK and the antagonist {[}H-3]NPC17731 to particulate fractions of human foreskin fibroblasts was studied.
Er Faussner, Faussner, Alexander, Adelbert A. Roscher, Roscher, Adelbert A.   +3 more
core   +1 more source

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3Research in context

EBioMedicine
Summary: Background: Amylin (AmyR) and calcitonin (CTR) receptor co-agonists are currently in Phase II/III clinical trials for obesity treatment. Amylin binds to a heterodimeric receptor composed of CTR and the receptor activity modifying proteins 1, 2 ...
Alexandra Oliveira Carvas, Andrea Leuthardt, Patricia Kulka, Greta Lommi, Shad Hassan, Bernd Coester, Sofia Lundh, Tune Pers, Anna Secher, Kirsten Raun, Thomas A. Lutz, Christelle Le Foll   +11 more
doaj   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects

Pharmacology Research & Perspectives
Obesity, a global health challenge, necessitates innovative approaches for effective management. Targeting gut peptides in the development of anti‐obesity pharmaceuticals has already demonstrated significant efficacy.
Igor Rubinić, Marija Kurtov, Robert Likić   +2 more
doaj   +1 more source